News

News 23.09.2025 CINCINNATI, September 22, 2025 — Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG (“Proteomedix”) has  signed a licensing agreement, with Immunovia...

News 23.09.2025 BOSTON, Massachusetts and ZUERICH, Switzerland – September 22, 2025 (GLOBE NEWSWIRE) – Biognosys, a pioneer in next-generation proteomics services and software, today announced the expansion of its contract research organization (CRO) services to include quantitative biocrates metabolomics and lipidomics. These services will be offered both in Europe as well as...

News 11.09.2025 Urdorf, Zurich — SecureCell has launched the Numero 3 automated sampling system. The system enables laboratories to reduce their manual workload and generate more reliable data. A webinar on October 15 will discuss the advantages of the Numero 3 system. The biotech company SecureCell AG, based in Urdorf, has further developed...

News 10.09.2025 Switzerland, 10 September 2025 – CUTISS, a late-stage clinical TechBio at the forefront of tissue therapeutics and regenerative medicine, has announced the closing of its Series C round for a total of CHF 56M with existing and new investors, bringing total funds raised to more than CHF 125M. The proceeds will...

News 09.09.2025 Topadur Pharma AG today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational therapy TOP-N53 for the treatment of digital ulcersin patients with systemic sclerosis. Systemic sclerosis is a rare, life-threatening autoimmune disease characterized by fibrosis, vascular damage, and chronic digital ulcers that...